Woes surround Cognac and its ongoing slump requires urgent attention
The Cognac region was at its autumnal best: Indian summer sunshine, the dark green vine leaves contrasting with the bleached chalk soils of the pristine Grande Champagne vineyards, a bumper crop of grapes safely gathered in. And yet there was an unmistakably gloomy atmosphere around the place, which seemed out of kilter with a category that remained – to all appearances – on a post-pandemic tear of growth.
This was October 2023 – only 18 months ago, and yet an age away in terms of the health of the Cognac category. What the Cognacais already knew, and the rest of us were later to find out, was that their world was beginning to turn. Warehouses groaning with stock in the US; China failing to pick up as expected following the easing of Covid-19 restrictions.
In 2021, at the peak of the post-pandemic surge, 223.2m bottles of Cognac were shipped around the world. The number in 2022 – 212.5m bottles – was billed as a return to normality, being only 4m bottles shy of the pre-pandemic total of 216.5m bottles, recorded in 2019.
Then came 2023: shipments totalling 165.3m bottles. That's a drop of 26% versus 2021, and 24% compared to 2019. Hardly surprising, then, that I encountered so much angst during that October visit to the region. Nonetheless, Cognac generic body the BNIC sought to reassure, citing temporary overstocking issues and predicting a return to pre-Covid shipment levels from 2024 onwards.
Instead, however, 2024 saw Cognac treading water, with shipments barely rising to 166m bottles. Worse still, value dipped by more than 10% to fall below €3bn (in 2022, it stood at €3.9bn).
That discrepancy between the volume and value trends is easily explained. While shipments of younger, typically VS Cognacs rose by 13.7% last year, VSOP shipments dropped by 8.6% and XO by 26.4%. (There's one reason for this slump – China – but we'll get to that in a moment.)
This depressing dynamic has played out in the recent results announcements from the Cognac industry's biggest players. Moët Hennessy's first quarter Cognac and spirits revenues down 17% to €736m, thanks to 'soft demand' in China and the US: Rémy Cointreau's 2024/25 Cognac sales plummeting 21.9% to €611.8m.
Rémy's figures are particularly dispiriting for a business that, even after recent declines, relies on Cognac for 62% of its revenue pool. The grim news coming out of China was leavened somewhat by a sharp recovery in the US, with the company tactically focusing on its entry-level VSOP product in a market that has long been a driver of volume rather than value.
Rémy has endured two years of constantly declining revenues, something which may or may not have been a factor in the announcement that Eric Vallat was stepping down as CEO, with board chair Marie-Amelie de Leusse taking on the role on an interim basis while a replacement is found.
We're told that Vallat will be pursuing 'a new professional project' from this summer, which is almost as vague as the traditional tropes employed in these announcements, such as 'personal reasons' or 'pursuing their career elsewhere'. The lack of succession planning suggests that one party or the other had concluded that enough was enough.
It's fair to say that most of Cognac's recent travails have been beyond the industry's control. Covid-19, the artificial demand bubble that followed it, the delayed economic consequences of the pandemic – and now tariffs and trade wars.
But these problems are accentuated by the category's over-reliance on two regions – NAFTA and the Far East – or rather two countries: the US and China. Even after the difficulties of the past couple of years, NAFTA accounted for 43% of global Cognac shipments in 2024, with the Far East at 29% (and Europe at 19%).
The promising evolution of South Africa – now an 8m-bottle market – offers a tantalising glimpse of what might have been, had Cognac's four leading brands worked harder to develop new markets during the good years, as a hedge against times like these.
Events in the US are deeply worrying, not just because of the delayed possibility of 20% tariffs (although a 10% tariff still applies in the meantime), but also because of the sheer uncertainty of dealing with the economic whims of the Trump administration.
But the situation in China is more serious still. Following the Ministry of Commerce's (Mofcom) provisional decision to impose additional duties of 38.1% on Cognac (and Armagnac, and other EU brandies), its anti-dumping investigation has been extended until at least 5 July.
This news prompted a joint response from the BNIC, Armagnac body the BNIA and FEVS (Fédération des Exportateurs de Vins et Spiritueux de France), following the visit of Jean-Noël Barrot, France's Minister of Foreign Affairs, to China on 27-28 March.
You can feel the caution running through the text, as the bodies cautiously welcome the extension of the probe, as well as hints that the stockpiles of Cognac sitting in Chinese ports might be permitted to be sold in duty free (the channel has been technically suspended in China since the announcement of the provisional tariffs, with a major impact on trade).
But then comes the kicker: 'However, in substance, these developments do not alter the situation for Cognac exporters, who have been subjected to provisional taxes in China since last October. For Cognac alone, these taxes have effectively excluded them from their second-largest market, resulting in a 72% drop in shipments, particularly for the month of February alone.'
Because of the nature of the Cognac industry, dominated as it is by four huge brands – Hennessy, Martell, Rémy Martin and Courvoisier – it's easy to simply view the consequences of the situation in China (and the US) through a corporate prism. Organic revenue declines, profit margins slashed.
What the BNIC/BNIA/FEVS joint press release hints at, however, is the deeper impact on an entire region. Urging all parties to resolve the China anti-dumping dispute, it continues: 'This additional period [until 5 July] must be used to find a diplomatic solution to remove our industry from this economic dispute, to which it is entirely unrelated, and which currently threatens to plunge it into a devastating and historic economic and social crisis.'
Hyperbole? I'm not so sure. Beyond the glitzy bottles of Louis XIII and Richard Hennessy, the Cognac region is a complex, interdependent ecosystem that encompasses brand owners, distillers, winegrowers and more. For all the luxury, it's still an agricultural industry.
There may be four dominant brands in Cognac, but there are also 4,360 winegrowers and distillers, 130 professional distillers, 14,500 direct jobs and 72,500 people whose livelihoods depend on people continuing to knock back Sidecars and sip glasses of XO. If the current slump isn't arrested, and arrested soon, there'll be a lot more than company share prices at stake.
"Woes surround Cognac and its ongoing slump requires urgent attention" was originally created and published by Just Drinks, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Miles Education and St. James School of Medicine partner to enable Indian NEET Qualifiers to become Licensed U.S. Doctors
BANGALORE, India, June 4, 2025 /PRNewswire/ -- Miles Education, a global ed-tech leader in outcome-driven international programs, today announced the official launch of the Miles MBBS-MD U.S. Pathway in a strategic partnership with St. James School of Medicine (SJSM), an accredited Caribbean medical school with clinical rotations and residency placements across the United States. The initiative directly addresses two major global healthcare challenges: India's acute shortage of medical seats and the United States' growing demand for licensed physicians. Each year, over 20 lakh Indian students sit for NEET UG, yet only about 120,000 secure a seat—leaving millions of qualified students behind due to limited capacity and sky-high private college fees. At the same time, the U.S. is projected to face a shortfall of 86,000 doctors by 2036, according to the Association of American Medical Colleges (AAMC), with rural and underserved communities being hit the hardest. International Medical Graduates (IMGs) already make up nearly 25% of the U.S. physician workforce and demand continues to rise. The Miles U.S. MBBS–MD Pathway directly addresses both crises by offering Indian NEET UG qualifiers an affordable and high-quality route to become licensed U.S. and Indian doctors. As a part of this program, students complete their pre-clinical coursework in the Caribbean, followed by clinical rotations and residency placements in the U.S., preparing them to clear all three steps of the USMLE and secure a U.S. medical license. All this at 50% lower tuition than Indian private colleges and an earning potential of U.S. Doctor Salaries which is approximately 10x of Indian MBBS and MD. This pathway gives students direct access to American healthcare, which is recognised as one of the most advanced medical systems in the world. Through this experience, Indian candidates gain exposure to world-class medical education and hospital systems. It offers them the opportunity to return and contribute to the Indian healthcare landscape, bringing back global best practices and innovations. As flagbearers of Indian medical talent, these professionals play a vital role in elevating the standard of care and aligning Indian healthcare with global benchmarks. Harsh Jain, Co-Founder and Executive Director of Miles Education, shared: "This initiative is very close to my heart. Medical education in India has become an elitist pursuit. The truth is, some of the most extraordinary doctors come from humble beginnings, driven by passion and determination. Yet today, limited medical seats and barriers make it harder for many talented students to follow their dreams. That's why we're committed to creating a pathway that breaks down these walls, opening doors for aspiring doctors across India to fulfill their dreams and become world-class physicians." Dr. Kallol Guha, PhD, DSc, Founder and President of Saint James School of Medicine, added: "For over 25 years, SJSM has served hundreds of U.S. and Canadian students with quality, accessible medical education. Now, with Miles as our exclusive India partner, we are very happy to open our doors to Indian students. Together, we can transform the affordability and accessibility of global medical education for India's youth. This is a goal that I have envisioned for many years now, and I'm glad that it is finally coming to fruition." Shirsha Guha, COO of St. James School of Medicine said: "We are proud to partner exclusively with Miles Education to provide Indian students a pathway that combines U.S.-standard training with affordability and strong clinical outcomes. This program prepares students to match into competitive U.S. residencies and pursue global medical careers. Our institution has been training doctors from the US and Canada for 25 years, it's time that Indian students too get to benefit from this pathway." About Miles Education Miles Education a global ed-tech leader, working backwards from industry shortages, skill gaps, and emerging opportunities to empower businesses and professionals across accounting, business, healthcare, and tech. By creating innovative pathways, Miles is building a robust ecosystem that sets talent up for success. About St. James School of Medicine SJSM, with campuses in the Caribbean, delivers a U.S.-modeled MD program designed for clinical excellence. With a focus on affordability, U.S. licensure readiness, and proven residency outcomes, SJSM is a trusted institution for aspiring international physicians. For more information, visit: Media contact: info@ Logo - View original content:
Yahoo
an hour ago
- Yahoo
‘Phasmophobia' Film in the Works: Blumhouse Developing Adaptation of Horror Video Game
Blumhouse Productions has set its sights on another horror video game to adapt to film, developing a feature based on 'Phasmophobia,' the first-person paranormal puzzle title that became a viral sensation during the COVID pandemic. The film adaptation will be produced by Blumhouse and Atomic Monster, in association with Kinetic Games Limited. No distributor or release date has been set. More from Variety 'M3GAN 2.0' Trailer: M3GAN Gets an Upgrade and Faces Another Killer Robot in Horror Sequel 'M3GAN 2.0' Teaser Has the Killer Doll Dancing to Chappell Roan's 'Femininomenon' and Proclaiming: 'The B-- Is Back' Box Office: 'Speak No Evil' Pipes in With $4.9 Million Opening Day, 'Beetlejuice 2' Still Shaking on Top First released in early access in 2020, 'Phasmophobia' became a social media fixation as Twitch streamers and YouTubers quickly took to the multiplayer ghost-hunting video game. Developed and released by Kinetic Games Limited, the title was a breakthrough hit for the indie banner, becoming the best-selling video game on Steam for several weeks through the final months of that year. It has been ported to several consoles and has sold more than 23 million copies globally in the time since. 'Phasmophobia' was also a critical darling, taking the prize in the category of best debut game at the 2020 Game Awards. The project was unveiled at the first-ever 'Business of Fear' event in Hollywood on Tuesday, which featured Blumhouse CEO Jason Blum and president Abhijay Prakash as speakers. It comes as Blumhouse's latest video game adaptation, following their 2023 title 'Five Nights at Freddy's' — another film based on a streamer-popularized horror game. That Universal release grossed $291 million worldwide — an especially impressive figure, considering it had a simultaneous streaming debut on Peacock in North America. A sequel, 'Five Nights at Freddy's 2,' will be released to theaters on Dec. 5. Blumhouse also sports a game division, with upcoming titles including 'Eyes of Hellfire' and 'Sleep Awake.' Best of Variety What's Coming to Netflix in June 2025 New Movies Out Now in Theaters: What to See This Week 'Harry Potter' TV Show Cast Guide: Who's Who in Hogwarts?
Yahoo
an hour ago
- Yahoo
Miles Education and St. James School of Medicine partner to enable Indian NEET Qualifiers to become Licensed U.S. Doctors
BANGALORE, India, June 4, 2025 /PRNewswire/ -- Miles Education, a global ed-tech leader in outcome-driven international programs, today announced the official launch of the Miles MBBS-MD U.S. Pathway in a strategic partnership with St. James School of Medicine (SJSM), an accredited Caribbean medical school with clinical rotations and residency placements across the United States. The initiative directly addresses two major global healthcare challenges: India's acute shortage of medical seats and the United States' growing demand for licensed physicians. Each year, over 20 lakh Indian students sit for NEET UG, yet only about 120,000 secure a seat—leaving millions of qualified students behind due to limited capacity and sky-high private college fees. At the same time, the U.S. is projected to face a shortfall of 86,000 doctors by 2036, according to the Association of American Medical Colleges (AAMC), with rural and underserved communities being hit the hardest. International Medical Graduates (IMGs) already make up nearly 25% of the U.S. physician workforce and demand continues to rise. The Miles U.S. MBBS–MD Pathway directly addresses both crises by offering Indian NEET UG qualifiers an affordable and high-quality route to become licensed U.S. and Indian doctors. As a part of this program, students complete their pre-clinical coursework in the Caribbean, followed by clinical rotations and residency placements in the U.S., preparing them to clear all three steps of the USMLE and secure a U.S. medical license. All this at 50% lower tuition than Indian private colleges and an earning potential of U.S. Doctor Salaries which is approximately 10x of Indian MBBS and MD. This pathway gives students direct access to American healthcare, which is recognised as one of the most advanced medical systems in the world. Through this experience, Indian candidates gain exposure to world-class medical education and hospital systems. It offers them the opportunity to return and contribute to the Indian healthcare landscape, bringing back global best practices and innovations. As flagbearers of Indian medical talent, these professionals play a vital role in elevating the standard of care and aligning Indian healthcare with global benchmarks. Harsh Jain, Co-Founder and Executive Director of Miles Education, shared: "This initiative is very close to my heart. Medical education in India has become an elitist pursuit. The truth is, some of the most extraordinary doctors come from humble beginnings, driven by passion and determination. Yet today, limited medical seats and barriers make it harder for many talented students to follow their dreams. That's why we're committed to creating a pathway that breaks down these walls, opening doors for aspiring doctors across India to fulfill their dreams and become world-class physicians." Dr. Kallol Guha, PhD, DSc, Founder and President of Saint James School of Medicine, added: "For over 25 years, SJSM has served hundreds of U.S. and Canadian students with quality, accessible medical education. Now, with Miles as our exclusive India partner, we are very happy to open our doors to Indian students. Together, we can transform the affordability and accessibility of global medical education for India's youth. This is a goal that I have envisioned for many years now, and I'm glad that it is finally coming to fruition." Shirsha Guha, COO of St. James School of Medicine said: "We are proud to partner exclusively with Miles Education to provide Indian students a pathway that combines U.S.-standard training with affordability and strong clinical outcomes. This program prepares students to match into competitive U.S. residencies and pursue global medical careers. Our institution has been training doctors from the US and Canada for 25 years, it's time that Indian students too get to benefit from this pathway." About Miles Education Miles Education a global ed-tech leader, working backwards from industry shortages, skill gaps, and emerging opportunities to empower businesses and professionals across accounting, business, healthcare, and tech. By creating innovative pathways, Miles is building a robust ecosystem that sets talent up for success. About St. James School of Medicine SJSM, with campuses in the Caribbean, delivers a U.S.-modeled MD program designed for clinical excellence. With a focus on affordability, U.S. licensure readiness, and proven residency outcomes, SJSM is a trusted institution for aspiring international physicians. For more information, visit: Media contact: info@ Logo - View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data